Therapeutic drug monitoring in rheumatic diseases: Utile or futile?

Rheumatology (United Kingdom)

Volumn 53, Issue 6, 2014, Pages 988-997

  Stamp, Lisa K ^a,b   Barclay, Murray ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Allopurinol; Methotrexate; Rheumatology; Therapeutic drug monitoring

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; COLCHICINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; OXIPURINOL; POLYGLUTAMIC ACID; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; DISEASE ACTIVITY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG MONITORING; ERYTHROCYTE; GOUT; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ALLOPURINOL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; GOUT SUPPRESSANTS; HUMANS; METHOTREXATE; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900821492     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket355     Document Type: Review

References (53)

1. Smolen J, Aletaha D, Bijlsma J et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Singh J, Furst D, Bharat A et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
3. Gearry R, Barclay M. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20: 1149-57.
4. Hung S, Chung W, Liou L et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102: 4134-9.
5. Lafforgue P, Monjanel-Mouterde S, Durand A et al. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995;22:844-9.
6. Dalrymple JM, Stamp LK, O'Donnell JL et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299-308.
7. Stamp LK, O'Donnell JL, Chapman PT et al. Determinants of red blood cell methotrexate polyglutamate concentrations in patients with rheumatoid arthritis on long-term MTX. Arthritis Rheum 2009;60:2248-56.
8. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology 2010;49:2337-45.
9. Seideman P. Preliminary report: methotrexate-the relationship between dose and clinical effect. Br J Rheum 1993;32:751-3.
10. Korell J, Duffull S, Dalrymple J et al. Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. Br J Clin Pharmac 2013. Advance Access published 11 July 2013, doi: 10.1111/ bcp.12209.
11. van Haandel M, Leeder J, Becker M. Measurement of methotrexate metabolites in peripheral blood mononuclear cells in juvenile idiopathic arthritis: a more relevant cellular biomarker for drug response? Arthritis Rheum 2011;63:S95.
12. Chaparro M, Guerra I, Munoz-Linares P et al. Systematic review: antibodies and anti-TNF-a levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:971-86.
13. Mulleman D, Méric J-C, Paintaud G et al. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 2009;11: R178.
14. Rahman M, Strusberg I, Geusens P et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-38.
15. Bartelds G, Krieckaert C, Nurmohamed M et al. Development of antidrug antibodies against adalimumab adn association with disease activity and treatment failure during long-term followup. JAMA 2011; 305:1460-68.
16. Ducourau E, Mulleman D, Paintaud G et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Care Res 2011;13:R105.
17. Radstake T, Svenson M, Eijsbouts A et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68:1739-45.
18. Vincent F, Morand E, Murphy K et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real clinical issue, a clinical perspective. Ann Rheum Dis 2013;72: 165-78.
19. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B et al. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology 2007;46:529-32.
20. Pavelka K, Jarosóvá K, Suchý D et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68:1285-89.
21. Stamp L, Zhu X, Dalbeth N et al. Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfils the OMERACT validation criteria for soluble biomarkers. Semin Arthritis Rheum 2011;40:483-500.
22. Dalbeth N, Kumar S, Stamp L et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout. J Rheumatol 2006;33:1646-50.
23. Murrell G, Rapeport W. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet 1986;11:343-53.
24. Hande K, Noone R, Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
25. Emmerson B, Gordon R, Cross M et al. Plasma oxypurinol concentrations during allopurinol therapy. Br J Rheumatol 1987;26:445-9.
26. Peterson G, Boyle R, Francis H et al. Dosage prescribing and plasma oxypurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol 1990; 39:419-21.
27. Stamp L, Barclay M, O'Donnell J et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharm Ther 2011;90:392-8.
28. Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol 2008;14:6-11.
29. Casas E, Puig J, Mateos F et al. The allopurinol hypersensitivity syndrome: its relation to plasma oxypurinol levels. Adv Exp Med Biol 1989;253A:257-60.
30. Puig J, Casas E, Ramos T et al. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J Rheumatol 1989;16:842-4.
31. Elasy T, Kaminsky D, Tracy M et al. Allopurinol hypersensitivity syndrome revisited. West J Med 1995;162: 360-1.
32. Achtert G, Scherrmann J, Christen M. Pharmacokinetics/ bioavailability of colchicine in healthy male volunteers. Eur J Drug Metab Pharmacokinet 1989;14:317-22.
33. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998;28:48-59.
34. U.S. Food and Drug Administration. New safety information for colchicine. 2009. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm 174315.htm (30 October 2013, date last accessed).
35. Terkeltaub R, Furst D, Kook K et al. New dosing guidelines for colchicine to avoid toxicity when used with Ca2+ channel blockers: the potent P-Gp/CYP3A4 inhibitor verapamil increases maximal concentration of single dose colchicine by 30% and exposure by -100% in healthy subjects. Arthritis Rheum 2009;60:S414.
36. Kintz P, Jamey C, Tracqui A et al. Colchcine poisoning: report of a fatal case and presentation of HPLC procedure for body fluid and tissue analysis. J Anal Toxicol 1997;21: 70-2.
37. Schedel J, Goddde A, Schütz E et al. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases. Ann N Y Acad Sci 2006;1069: 477-91.
38. Schmiegelow K, Kreigbaum N. 6-Thioguanine nucleotide accumulation in erythrocytes during azathioprine treatment for systemic connective tissue diseases: a possible index for monitoring treatment. Ann Rheum Dis 1993;52: 152-4.
39. Francès C, Cosnes A, Duhaut P et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus. Arch Dermatol 2012; 148:479-84.
40. Costedoat-Chalumeau N, Amoura Z, Hulot J et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54: 3284-90.
41. Angelis-Stoforidis P, Vajda FJE, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999; 17:313-20.
42. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
43. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic markers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006;54: 3095-103.
44. Hornung N, Ellingsen T, Attermann J et al. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol 2008;35:1709-15.
45. Stamp LK, O'Donnell JL, Chapman PT et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients on longterm MTX therapy. Arthritis Rheum 2010;62:359-68.
46. Becker M, Gaedigk R, Van Haandel L et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011;63:276-85.
47. Hobl E-L, Jilma B, Erlacher L et al. A short chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol 2012;30:156-63.
48. St. Clair E, Wagner C, Fasanmade A et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-59.
49. Wolbink G, Voskuyl A, Lems W et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:704-7.
50. Mulleman D, Lin D, Ducourau E et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010;32:232-6.
51. Bartelds G, Wijbrandts C, Nurmohamed M et al. Clinical response to adalimumab: relationship to antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
52. Jamnitski A, Krieckaert C, Nurmohamed M et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
53. Daien C, Daien V, Parussini E et al. Etanercept concentrations in patients with rheuamtoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 2012;39:1533-8.